Ono Pharmaceutical Company Description
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.
The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders.
The company was founded in 1717 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1717 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 4,287 |
| CEO | Gyo Sagara |
Contact Details
Address: 8-2, Kyutaromachi 1-chome Osaka, 541-8564 Japan | |
| Phone | 81 6 6263 5670 |
| Website | ono-pharma.com |
Stock Details
| Ticker Symbol | OPHLY |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | US6827361030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gyo Sagara | Chief Executive Officer and Chairman of the Board |
| Toichi Takino Ph.D. | President, Chief Operating Officer and Representative Director |
| Masaki Ito | Corporate Offcr. and Div. Dir. of Corp. Strategy and Planning, Business Mgmt., and Corp. Tax |
| Takehiro Yamada | Corporate Officer and Head of Risk and Compliance Management Department |
| Masayuki Tanigawa | Corporate Officer and Head of Business Strategy Headquarters |
| Hiromu Habashita Ph.D. | Corporate Officer and Deputy Executive Director, Discovery & Research |
| Shinji Takai M.D., Ph.D. | Corporate Officer and Head of Medical Affairs |
| Satoshi Takahagi | Senior Director of EHS Promotion and Corporate Executive Officer |
| Akira Takada | Corporate Executive Officer &Exe. Dir. of CMC and Production |
| Tatsuya Okamoto | Head of Development Div., Oncology Clinical Development Div. and Global Development Management Unit |